Note: ASCO and CAP are committed to keeping this guideline up to date. We are currently monitoring the literature to determine if a revision is needed or if we will reaffirm the recommendations.
Note that recommendations in the 2007 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline for Human Epidermal Growth Factor Receptor 2 (HER2) Testing have been reconciled with the April 2010 ASCO/CAP Estrogen (ER) and Progesterone Receptor (PgR) Guideline so that cancer specimens will be handled in a uniform manner for ER, PgR, and HER2 in breast cancer specimens.
In the Journal of Clinical Oncology, a joint letter to the editor by Elizabeth Hammond, MD, Daniel F. Hayes, MD and Antonio Wolff, MD, co-chairs of the ASCO/CAP guideline panels provides an important reminder of the intent of the ASCO and CAP guideline panel on HER2 Testing.
The letter also reconciles some pathology technical aspects with the recent guideline on Immunohistochemical Testing of Estrogen and Progesterone Receptor (ER and PgR) Testing in breast cancer.